Linked Life Data

8933004

Source:http://linkedlifedata.com/resource/pubmed/id/8933004

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
1997-3-17
pubmed:abstractText
To determine the value of antibodies to the intracytoplasmic domain of the tyrosine phosphatase IA-2 (anti-IA-2ic) and glutamic acid decarboxylase (GADA) for identification of subjects at risk for insulin-dependent diabetes mellitus (IDDM) we investigated 1238 first degree relatives of patients with IDDM for the presence of anti-IA-2ic and GADA and compared the results with cytoplasmic islet cell antibodies (ICA). Anti-IA-2ic were observed in 54 (4.4%) first degree relatives, in 51 of 86 (59.3%) ICA positive relatives and in 3 of 4 individuals who developed overt IDDM within a follow-up period of 1 to 28 months. GADA were found in 78 of 1238 (6.3%) first degree relatives. They were detected in 22 of 35 (62.9%) sera with ICA alone and in 1 of 3 subjects with anti-IA-2ic in the absence of ICA. Of the 1238 subjects 37 (3.0%) sera were positive for all three antibodies. Both anti-IA-2ic and GADA were positively correlated with high levels of ICA. Anti-IA-2ic and GADA were detected in 39.1 and 47.8% of subjects with ICA of less than 20 Juvenile Diabetes Foundation units (JDF-U) but in 66.7 and 76.2% of individuals with ICA of 20 JDF-U or more, respectively (p < 0.05). The levels of ICA and GADA in first degree relatives with at least one additional marker were significantly higher than in subjects with ICA alone (p < 0.005) or GADA alone (p < 0.03). The combination of anti-IA-2ic and GADA identified 84.9% of all ICA positive subjects and 93.7% of individuals with high level ICA (> or = 20 IDF-U). All 4 individuals who progressed to IDDM had either IA-2ic or GADA. Our data indicate that primary screening for anti-IA-2ic and GADA provides a powerful approach with which to identify subjects at risk for IDDM in large-scale population studies which may represent the basis for the design of new intervention strategies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0012-186X
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1351-6
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:8933004-Adolescent, pubmed-meshheading:8933004-Adult, pubmed-meshheading:8933004-Age Distribution, pubmed-meshheading:8933004-Autoantibodies, pubmed-meshheading:8933004-Biological Markers, pubmed-meshheading:8933004-Child, pubmed-meshheading:8933004-Child, Preschool, pubmed-meshheading:8933004-Diabetes Mellitus, Type 1, pubmed-meshheading:8933004-Family, pubmed-meshheading:8933004-Female, pubmed-meshheading:8933004-Fluorescent Antibody Technique, Indirect, pubmed-meshheading:8933004-Follow-Up Studies, pubmed-meshheading:8933004-Glutamate Decarboxylase, pubmed-meshheading:8933004-Humans, pubmed-meshheading:8933004-Infant, pubmed-meshheading:8933004-Islets of Langerhans, pubmed-meshheading:8933004-Male, pubmed-meshheading:8933004-Middle Aged, pubmed-meshheading:8933004-Prevalence, pubmed-meshheading:8933004-Protein Tyrosine Phosphatase, Non-Receptor Type 1, pubmed-meshheading:8933004-Protein Tyrosine Phosphatases, pubmed-meshheading:8933004-Radioligand Assay, pubmed-meshheading:8933004-Recombinant Proteins, pubmed-meshheading:8933004-Risk Factors
pubmed:year
1996
pubmed:articleTitle
Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. The DENIS Study Group. Deutsche Nikotinamid Interventions-Studie.
pubmed:affiliation
Department of Internal Medicine III, University of Leipzig, Germany.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't